Table 3.
Patient number | Type of CTL | Antitumor l effects | Reference |
---|---|---|---|
Non-Hodgkin’s and Hodgkin’s Lymphoma | |||
10 | LCL-induced | 2 CRs, 1 PR, 5 stable disease | Bollard et al. 2004 (50) |
50 | LMP-specific T cells using autologous dendritic cells and LCL transduced with an adenoviral vector expressing LMP2 or LMP1/2 | Prophylaxis: 28 of 29 remain disease-free with median of 3 years follow up Treatment. 11 of 21 CRs, 2 PRs |
Bollard et al. 2007(51) Bollard et al. 2013 (17) |
3 | LCL-induced from HLA-identical sibling (2) or autologous (1) | Stable disease for > 3 years in 2 | Cho et al. 2006 (100) |
Nasopharyngeal cancer | |||
4 | LCL-induced | Reduction in viral load but no clinical responses | Chua et al. 2001(101) |
10 | LCL-induced | 2 PR and 4 with stable disease | Comoli et al. 2005 (6) |
23 | LCL-induced | Prophylaxis: 5 of 8 patients treated adjuvantly remained disease-free for 25 to 82 months and 3 relapsed. Treatment. 5 with CR, 2 with PR, 3 with Stable Disease, 5 with progression |
Straathof et al. 2005 (53) Louis et al. 2010 (5) |
8 | LCL-induced after lymphodepletion with CD45 | 1 CR and 2 stable diseases | Louis et al. 2009 (54) |
11 | LCL-induced after cyclophosphamide and fludarabine | 2 PRs, 3 with stable disease, 1 minor response | Secondino et al. (55) |
35 | LCL-induced after standard chemotherapy for metastatic disease | 2-year overall survival OS was 67.2% | Teo et al. (30) |
Abbreviations: LCL, lymphoblastoid cell line; LMP, latent membrane protein; CR, complete remission; PR, partial remission,